Navigation Links
New Data Validates CyberKnife SBRT for Prostate Cancer Treatment
Date:5/21/2013

SUNNYVALE, Calif., May 21, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the publication of study results involving hundreds of prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System, the most widely used form of prostate stereotactic body radiation therapy (SBRT). The study followed 304 patients for a median of 5 years, and many to 6 years post-treatment and found that 97 percent of patients with low-risk and 90.7% of patients with intermediate-risk prostate cancer remained cancer-free throughout that time. The CyberKnife treatment was also shown to be minimally harmful, producing low levels of toxicity that are similar to the level produced by other radiation treatment options including brachytherapy. Preservation of sexual function was achieved for 75 percent of patients who were sexually potent prior to CyberKnife treatment. The positive quality of life outcomes, low side effects, and brief duration of CyberKnife treatment are especially encouraging for men weighing their many treatment options.

"Stereotactic Body Radiotherapy for Localized Prostate Cancer: Disease Control and Quality of life at 6 Years," appears in the May 2013 edition of Radiation Oncology and was led by Dr. Alan Katz , a radiation oncologist with more than 30 years of experience who currently practices at Flushing Radiation Oncology in Queens, N.Y.

In related SBRT news, the American Society for Radiation Oncology (ASTRO) recently updated its position on the use of SBRT for prostate cancer. According to its recently posted Model Policy, the Society believes that enough clinical evidence now exists to so that "SBRT could be considered an appropriate alternative for select patients with low to intermediate risk disease."

"These latest long-term CyberKnife data coupled with ASTRO's new position on SBRT for prostate cancer confirm what I have seen in my clinical practice," said Dr. Alan Katz . "CyberKnife SBRT is a safe and effective treatment for prostate cancer that offers men the opportunity to complete a non-invasive treatment in five days and should be considered for patients with organ-confined prostate cancer."

"Dr. Katz's five-year CyberKnife prostate SBRT data show good disease-free survival, low toxicity, and preservation of sexual function. The data support prior findings that validate an approach to prostate SBRT that includes dynamic tracking and automatic correction for target motion," said Fabienne Hirigoyenberry-Lanson, vice president of medical affairs at Accuray.

The first five-year outcomes  on CyberKnife SBRT for prostate cancer patients were published in January 2011. For more information, please visit www.Accuray.com.

About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells personalized, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on September 10, 2012, as updated in our Form 10-Qs filed on November 8, 2012, February 6, 2013, and May 9, 2013 and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.  Accordingly, investors should not place undue reliance on any forward-looking statements.


'/>"/>
SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
2. Presentations at Leading Radiation Oncology Meeting Highlight CyberKnife Prostate Outcomes from Patients at More Than 40 Centers
3. CyberKnife Cancer Institute of Chicago Is the First to Offer CyberKnife Treatment in the City of Chicago
4. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
5. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
6. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
7. Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prostate Biopsy Outcome at American Urological Association Annual Meeting
8. SonaCare Medical to Integrate SmartTarget Image Registration and Fusion Software from University College London into Industry Leading Prostate HIFU System
9. Premier Prostate Cancer Center the Latest Center to Achieve High Honor of ACR Accreditation
10. Prostate Cancer Patient Receives First Treatment Using Latest Version of Vitesse Real-Time Brachytherapy Planning System from Varian Medical Systems
11. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2019)... ... June 18, 2019 , ... The ... for patients in the Bridgeville, PA area. Understanding the crippling effects patients experience ... Wayne DiBartola and Tyler Porco offer same-day oral sedation, nitrous oxide, and IV ...
(Date:6/16/2019)... ... , ... AVIE! MedSpa and Laser Center is proud to offer Vivace™ ... for achieving dramatic improvements to the texture and tightness of skin on any area ... with tiny needles, spurring vibrant new collagen growth for a wide range of complexion ...
(Date:6/16/2019)... ... June 15, 2019 , ... ... cell clinic offering state-of-the-art treatment with cutting-edge technology, has opened. , The ... the game-changing healing capabilities of regenerative medicine. , “Using the remarkable cutting-edge ...
Breaking Medicine Technology:
(Date:6/19/2019)... ... 19, 2019 , ... LifeLearn Animal Health launches PetInsuranceInfo.com, a new pet insurance ... isn’t, and the questions they need to ask prior to purchasing a policy. ... and find the coverage that meets their budget and pet’s health care needs. ...
(Date:6/18/2019)... , ... June 18, 2019 , ... ... addressing unmet needs in the field of urology, today announced that Aaron Berger, ... UroLift® Center of Excellence. The designation recognizes that Dr. Aaron Berger has achieved ...
(Date:6/16/2019)... ... June 16, 2019 , ... Ted Danson on CNBC will ... for the advancement of medical marijuana-based pharmaceuticals in an upcoming episode, scheduled to ... information. , With two investigational new drug applications already accepted by the FDA, ...
(Date:6/13/2019)... ... 13, 2019 , ... MMJ BioPharma Cultivation, a premier medical ... of understanding (MOU) with MMJ International Holdings to grow cannabis and supply active ... Cultivation will be supplying MMJIH with extracts from the marijuana plant to support ...
(Date:6/13/2019)... ... June 13, 2019 , ... Hard money lenders like ... hours and the funds can also be provided quickly. If the documentation and collateral ... lenders are able to avoid the federal oversight involved with a traditional lender, which ...
Breaking Medicine News(10 mins):